TympaHealth has raised £18.4m in Series A funding to expand access to its tech-enabled hearing assessment and diagnostic solution.

The London firm’s solution allows for fully digitised comprehensive ear and hearing health assessments to be performed across both traditional clinical and community-based settings. 

By creating a CE-marked, FDA-registered solution that brings ENT expertise to community settings, Tympa says it increases cost-effective access to care and supports earlier disease detection. 

The oversubscribed funding round, led by Octopus Ventures, was supported by follow-on investment from existing investors and welcomes new investors Dara Capital, Rezayat investments and serial entrepreneurs Bob Davis and Jeff Leerink. 

“Our goal is to make ear and hearing healthcare easily accessible to everybody, on a global scale,” said Dr Krishan Ramdoo, founder & CEO of TympaHealth. 

“Putting the right technology and support into the hands of more healthcare professionals and community providers is the best possible place to start. 

“We have had a fantastic last year with a significant customer base and to date we have supported more than 250,000 patients. The Tympa Platform has proven its benefits at every point in the healthcare value chain and with our new funding, we can expand that value to new partners and markets.” platform ‘to detect age-related diseases earlier’

The Tympa Platform allows a much broader range of professionals to perform digital otoscopy, microsuction wax removal and hearing assessments. Tympa’s examination is digitally captured in a single hearing health record, which can be shared between patients, providers and specialists. 

In the UK, TympaHealth has well established partnerships with providers including Walgreen Boots Alliance, Sonova, Day Lewis Pharmacy, Demant (Hidden Hearing), Bupa and the NHS to provide treatment through its platform. 

With this funding round, Tympa is growing its team and services in the UK, across Europe and entering into the US. Industry veteran David Horowitz, formerly of Oticon, joins as its new US vice president of sales.

Joe Stringer, partner at Octopus Ventures, added: “The TympaHealth proposition is a fantastic exemplar for the quality of high growth healthtech and life science businesses we have in the UK. 

“Using a high-quality product and a proposition geared around the consumer, they are reducing the burden of ear and hearing care in an overstretched NHS, while vastly improving patient experience and outcomes. 

“They are building exactly the kind of game changing business we look to support, and they are in a market with huge potential. We couldn’t be happier to be backing them as they seize that potential and democratise ear and hearing healthcare access globally.”

MedTech 50 – UK’s most innovative medical technology creators for 2022